Using blood tests to improve detection and monitoring of glioma
Circulating cell-free DNA methylation as an accurate tool for detection and clinical follow-up of glioma
This study is looking at how analyzing DNA from your blood can help doctors better detect and track brain tumors called gliomas, making it easier to monitor your condition without needing invasive tests.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health System NIH-funded |
| Lab location | 1 site (Detroit, United States) |
| Project ID | NIH-11042239 on NIH RePORTER |
What this research studies
This research investigates the use of blood-derived cell-free DNA methylation markers to enhance the detection and monitoring of gliomas, a type of brain tumor. By analyzing DNA from blood samples, the study aims to provide a more accurate method for identifying tumor progression and response to treatment compared to traditional imaging techniques. This approach seeks to minimize the need for invasive procedures and improve real-time surveillance of glioma patients. The ultimate goal is to refine treatment strategies based on the molecular profile of the tumor as indicated by the blood tests.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with malignant gliomas who are undergoing treatment or follow-up care.
Not a fit: Patients with non-glioma brain tumors or those not undergoing treatment for gliomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and less invasive monitoring of glioma progression, improving patient outcomes.
How similar studies have performed: Other research has shown promise in using liquid biopsy techniques for cancer monitoring, suggesting that this approach could be effective for gliomas as well.
Where this research is happening
Detroit, United States
- Henry Ford Health System — Detroit, United States (Active)
Researchers
- Principal investigator: Noushmehr, Houtan — Henry Ford Health System
- Study coordinator: Noushmehr, Houtan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.